Arshpreet Kaur, MD
Internal Medicine · Shreveport, LANPI 1992025233
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for internal medicine clinicians in LA, where the typical reported total is $379.
Across 9 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$36
- Amgen$34
- Valeritas, Inc.$23
- Johnson & Johnson$16
- Insulet Corporation$15
- Eisai Inc.$15
- plus $23 from 2 others
What the payments were for
- Food & beverage$162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $36 |
| Amgen | 2 | $34 |
| Valeritas, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Abbott | 1 | $12 |
| Pfizer | 1 | $11 |
How this compares
$162 in reported general payments places this provider in the 35th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 41 | $70,724 |
| TrulicityDulaglutide | 58 | $68,910 |
| OzempicSemaglutide | 49 | $59,412 |
| JardianceEmpagliflozin | 30 | $41,992 |
| Repatha SureclickEvolocumab | 16 | $9,697 |
| Praluent PenAlirocumab | 13 | $6,478 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $6,171 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $6,050 |
| Novolog FlexpenInsulin Aspart | 21 | $2,609 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,827 |
| Hydrocortisone | 14 | $502 |
| Levothyroxine Sodium | 44 | $283 |
| Metformin Hcl ErMetformin Hcl | 20 | $239 |
| Pregabalin | 14 | $153 |
| Methimazole | 33 | $103 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Shreveport
- Rajan KhannaShreveport$54K
- Wendell WallShreveport$25K
- Bharat SachdevaShreveport$24K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- Paul RushingShreveport$13K
- Allan Matriano-LimShreveport$12K
- Scott McRightShreveport$12K
- Furqan AkhtarShreveport$11K
- Roan FlennikenShreveport$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.